Findings

What do systematic reviews say?

15 questions · 15 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 46.7%GRADE not reported 0 · 0%Very low 2 · 13.3%Low 5 · 33.3%Moderate 1 · 6.7%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) · Overall survival (OS)
  Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) · Time to recurrence (TTR), measured by the number of disease recurrence events over time,
  Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Low
Direct match · question page
- Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) · Overall response rate (ORR),
  Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 10 participants
  Low
Direct match · question page
- Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) · Overall survival (OS), measured by number of deaths over timeMedian
  Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Moderate
Direct match · question page
- Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) · Overall response rate (ORR),
  Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 2.91 [1.02, 8.27]
  1 study · 23 participants
  Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Overall survival (OS) · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Adverse events, · stage III cutaneous melanoma

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 1 [0.75, 1.34]
1 study · 20 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Overall response rate (ORR), · stage III cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Time to recurrence ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Quality of life ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Death Number of deaths over 36 months · stage III and IV cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Moderate

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Adverse events, · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 8.73 [1.29, 59]
1 study · 23 participants
Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Overall response rate (ORR), · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 2.91 [1.02, 8.27]
1 study · 23 participants
Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Time to recurrence · stage III and IV cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Quality of life ‐ not measured · stage III and IV cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Overall survival (OS) · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Adverse events, · stage III cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Overall response rate (ORR), · stage III cutaneous melanoma

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in overall response rate (ORR), compared with neoadjuvant immunotherapy (sequential treatment with ipilimumab then… (low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 1.42 [0.87, 2.32]
1 study · 86 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Time to response ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Quality of life ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found